title: Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes.
authors.affiliation: Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.
authors.forename: Ali T
authors.initials: AT
authors.lastname: Taher
authors.affiliation: Department of Haematology, University College London, London, UK.
authors.forename: John B
authors.initials: JB
authors.lastname: Porter
authors.affiliation: First Department of Pediatrics, University of Athens, Athens, Greece.
authors.forename: Antonis
authors.initials: A
authors.lastname: Kattamis
authors.affiliation: Department of Pediatrics and Thalassemia Center, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
authors.forename: Vip
authors.initials: V
authors.lastname: Viprakasit
authors.affiliation: Department of Internal Medicine, Università di Milano, Ca Granda Foundation IRCCS, Milan, Italy.
authors.forename: M Domenica
authors.initials: MD
authors.lastname: Cappellini
mesh_terms: D001565:Benzoates; D015913:Chelation Therapy; D003676:Deferoxamine; D004359:Drug Therapy, Combination; D006801:Humans; D007501:Iron / Q000627:therapeutic use; D007502:Iron Chelating Agents; D011728:Pyridones; D013577:Syndrome; D013789:Thalassemia / Q000139:chemically induced; D014230:Triazoles
chemical_list: D001565:Benzoates; D007502:Iron Chelating Agents; D011728:Pyridones; D014230:Triazoles; D007501:Iron; D003676:Deferoxamine